{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T04:28:01Z","timestamp":1770956881676,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,1,27]],"date-time":"2017-01-27T00:00:00Z","timestamp":1485475200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100012479","name":"Weston Brain Institute","doi-asserted-by":"crossref","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100012479","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000263","name":"Parkinson Society Canada","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100000263","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Centre Hospitalier de l'Universite de Montreal","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s00213-017-4530-z","type":"journal-article","created":{"date-parts":[[2017,1,27]],"date-time":"2017-01-27T04:00:08Z","timestamp":1485489608000},"page":"905-911","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset"],"prefix":"10.1007","volume":"234","author":[{"given":"Adjia","family":"Hamadjida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen G","family":"Nuara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Veyres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imane","family":"Frouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lamia","family":"Sid-Otmane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mery-Jane","family":"Harraka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim C","family":"Gourdon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Huot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,27]]},"reference":[{"key":"4530_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJM199307153290303","volume":"329","author":"JM Alvir","year":"1993","unstructured":"Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the United States N Engl J Med 329:162\u2013167. doi: 10.1056\/NEJM199307153290303","journal-title":"Incidence and risk factors in the United States N Engl J Med"},{"key":"4530_CR2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","volume":"7","author":"SA Anttila","year":"2001","unstructured":"Anttila SA, Leinonen EV (2001) A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 7:249\u2013264","journal-title":"CNS Drug Rev"},{"key":"4530_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings J et al (2014) Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383:533\u2013540. doi: 10.1016\/S0140-6736(13)62106-6","journal-title":"Lancet"},{"issue":"Suppl 4","key":"4530_CR4","first-page":"19","volume":"57","author":"T Boer de","year":"1996","unstructured":"de Boer T (1996) The pharmacologic profile of mirtazapine. J Clin Psychiatry 57(Suppl 4):19\u201325","journal-title":"J Clin Psychiatry"},{"key":"4530_CR5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/00044011-199815010-00006","volume":"15","author":"LP Delbressine","year":"1998","unstructured":"Delbressine LP et al (1998) Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clinical drug investigation 15:45\u201355","journal-title":"Clinical drug investigation"},{"key":"4530_CR6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","volume":"62","author":"F Durif","year":"2004","unstructured":"Durif F et al (2004) Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62:381\u2013388","journal-title":"Neurology"},{"key":"4530_CR7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1017\/S0317167100009707","volume":"37","author":"SH Fox","year":"2010","unstructured":"Fox SH, Visanji N, Reyes G, Huot P, Gomez-Ramirez J, Johnston T, Brotchie JM (2010) Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson\u2019s disease. Can J Neurol Sci 37:86\u201395","journal-title":"Can J Neurol Sci"},{"key":"4530_CR8","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1001\/archneur.63.9.1343","volume":"63","author":"SH Fox","year":"2006","unstructured":"Fox SH, Visanji NP, Johnston TH, Gomez-Ramirez J, Voon V, Brotchie JM (2006) Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Arch Neurol 63:1343\u20131344. doi: 10.1001\/archneur.63.9.1343","journal-title":"Arch Neurol"},{"key":"4530_CR9","doi-asserted-by":"crossref","unstructured":"French Clozapine Parkinson Study Group (1999) Clozapine in drug-induced psychosis in Parkinson\u2019s disease. The French Clozapine Parkinson Study Group. Lancet 353:2041\u20132042","DOI":"10.1016\/S0140-6736(99)00860-0"},{"key":"4530_CR10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3233\/BEN-129016","volume":"27","author":"JH Friedman","year":"2013","unstructured":"Friedman JH (2013) Parkinson disease psychosis: update. Behav Neurol 27:469\u2013477. doi: 10.3233\/BEN-129016","journal-title":"Behav Neurol"},{"key":"4530_CR11","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1367014","author":"JA Godschalx-Dekker","year":"2014","unstructured":"Godschalx-Dekker JA, Siegers HP (2014) Reduction of parkinsonism and psychosis with mirtazapine. A Case Report Pharmacopsychiatry. doi: 10.1055\/s-0034-1367014","journal-title":"A Case Report Pharmacopsychiatry"},{"key":"4530_CR12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1212\/WNL.50.2.515","volume":"50","author":"CG Goetz","year":"1998","unstructured":"Goetz CG, Pappert EJ, Blasucci LM, Stebbins GT, Ling ZD, Nora MV, Carvey PM (1998) Intravenous levodopa in hallucinating Parkinson\u2019s disease patients: high-dose challenge does not precipitate hallucinations. Neurology 50:515\u2013517","journal-title":"Neurology"},{"key":"4530_CR13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1353-8020(02)00011-1","volume":"9","author":"PH Gordon","year":"2002","unstructured":"Gordon PH, Pullman SL, Louis ED, Frucht SJ, Fahn S (2002) Mirtazapine in Parkinsonian tremor. Parkinsonism Relat Disord 9:125\u2013126","journal-title":"Parkinsonism Relat Disord"},{"key":"4530_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/mds.20324","volume":"20","author":"MA Hely","year":"2005","unstructured":"Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney multicenter study of Parkinson\u2019s disease: non-L-dopa-responsive problems dominate at 15\u00a0years. Mov Disord 20:190\u2013199. doi: 10.1002\/mds.20324","journal-title":"Mov Disord"},{"key":"4530_CR15","doi-asserted-by":"publisher","first-page":"e45587","DOI":"10.1371\/journal.pone.0045587","volume":"7","author":"P Huot","year":"2012","unstructured":"Huot P, Johnston TH, Gandy MN, Reyes MG, Fox SH, Piggott MJ, Brotchie JM (2012) The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset. PLoS One 7:e45587. doi: 10.1371\/journal.pone.0045587","journal-title":"PLoS One"},{"key":"4530_CR16","doi-asserted-by":"publisher","first-page":"7190","DOI":"10.1523\/JNEUROSCI.1171-11.2011","volume":"31","author":"P Huot","year":"2011","unstructured":"Huot P et al (2011) Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of on-time. J Neurosci 31:7190\u20137198. doi: 10.1523\/JNEUROSCI.1171-11.2011","journal-title":"J Neurosci"},{"key":"4530_CR17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.neuropharm.2014.01.012","volume":"82","author":"P Huot","year":"2014","unstructured":"Huot P et al (2014) UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. Neuropharmacology 82:76\u201387. doi: 10.1016\/j.neuropharm.2014.01.012","journal-title":"Neuropharmacology"},{"key":"4530_CR18","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1097\/JCP.0b013e3182664d98","volume":"32","author":"E Jaquenoud Sirot","year":"2012","unstructured":"Jaquenoud Sirot E et al (2012) Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression. J Clin Psychopharmacol 32:622\u2013629. doi: 10.1097\/JCP.0b013e3182664d98","journal-title":"J Clin Psychopharmacol"},{"key":"4530_CR19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1124\/jpet.110.169532","volume":"336","author":"TH Johnston","year":"2011","unstructured":"Johnston TH et al (2011) Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson\u2019s disease. J Pharmacol Exp Ther 336:423\u2013430. doi: 10.1124\/jpet.110.169532","journal-title":"J Pharmacol Exp Ther"},{"key":"4530_CR20","first-page":"133","volume":"54","author":"K Kannari","year":"2002","unstructured":"Kannari K et al (2002) Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson\u2019s disease. No To Shinkei 54:133\u2013137","journal-title":"No To Shinkei"},{"key":"4530_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1212\/WNL.0b013e31825f0451","volume":"79","author":"PA Lewitt","year":"2012","unstructured":"Lewitt PA et al (2012) Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 79:163\u2013169. doi: 10.1212\/WNL.0b013e31825f0451","journal-title":"Neurology"},{"key":"4530_CR22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/00002826-198610000-00010","volume":"9","author":"A Maertens de Noordhout","year":"1986","unstructured":"Maertens de Noordhout A, Delwaide PJ (1986) Open pilot trial of ritanserin in parkinsonism. Clin Neuropharmacol 9:480\u2013484","journal-title":"Clin Neuropharmacol"},{"key":"4530_CR23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00002826-200307000-00005","volume":"26","author":"G Meco","year":"2003","unstructured":"Meco G, Fabrizio E, Di Rezze S, Alessandri A, Pratesi L (2003) Mirtazapine in L-dopa-induced dyskinesias. Clin Neuropharmacol 26:179\u2013181","journal-title":"Clin Neuropharmacol"},{"key":"4530_CR24","first-page":"262","volume":"43","author":"G Meco","year":"1988","unstructured":"Meco G, Marini S, Linfante I, Modarelli F, Agnoli A (1988) Controlled single-blind crossover study of ritanserin and placebo in L-dopa-induced dyskinesias in Parkinson\u2019s disease. Curr Ther Res 43:262\u2013270","journal-title":"Curr Ther Res"},{"key":"4530_CR25","doi-asserted-by":"publisher","unstructured":"Nagata T, Shinagawa S, Tagai K, Nakayama K (2012) A case in which mirtazapine reduced auditory hallucinations in a patient with Parkinson disease Int Psychogeriatr:1\u20133 doi: 10.1017\/S1041610212002037","DOI":"10.1017\/S1041610212002037"},{"key":"4530_CR26","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1017\/S1041610212002037","volume":"25","author":"T Nagata","year":"2013","unstructured":"Nagata T, Shinagawa S, Tagai K, Nakayama K (2013) A case in which mirtazapine reduced auditory hallucinations in a patient with Parkinson disease. Int Psychogeriatr 25:1199\u20131201. doi: 10.1017\/S1041610212002037","journal-title":"Int Psychogeriatr"},{"key":"4530_CR27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1055\/s-2007-979504","volume":"30","author":"C Normann","year":"1997","unstructured":"Normann C, Hesslinger B, Frauenknecht S, Berger M, Walden J (1997) Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine. Pharmacopsychiatry 30:263\u2013265","journal-title":"Pharmacopsychiatry"},{"key":"4530_CR28","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. The Parkinson Study Group. N Engl J Med 340:757\u2013763","DOI":"10.1056\/NEJM199903113401003"},{"key":"4530_CR29","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/mds.1143","volume":"16","author":"O Rascol","year":"2001","unstructured":"Rascol O et al (2001) Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson\u2019s disease. Mov Disord 16:708\u2013713","journal-title":"Mov Disord"},{"key":"4530_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/2008-2231-22-13","volume":"22","author":"MR Rouini","year":"2014","unstructured":"Rouini MR, Lavasani H, Sheikholeslami B, Owen H, Giorgi M (2014) Pharmacokinetics of mirtazapine and its main metabolites after single intravenous and oral administrations in rats at two dose rates. Daru 22:13. doi: 10.1186\/2008-2231-22-13","journal-title":"Daru"},{"issue":"Suppl 3","key":"4530_CR31","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1002\/mds.23884","volume":"26","author":"K Seppi","year":"2011","unstructured":"Seppi K et al (2011) The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov Disord 26(Suppl 3):S42\u2013S80. doi: 10.1002\/mds.23884","journal-title":"Mov Disord"},{"key":"4530_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1479-8301.2012.00432.x","volume":"13","author":"K Tagai","year":"2013","unstructured":"Tagai K, Nagata T, Shinagawa S, Tsuno N, Ozone M, Nakayama K (2013) Mirtazapine improves visual hallucinations in Parkinson\u2019s disease: a case report. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society 13:103\u2013107. doi: 10.1111\/j.1479-8301.2012.00432.x","journal-title":"Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society"},{"key":"4530_CR33","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.pbb.2008.04.010","volume":"90","author":"KE Vanover","year":"2008","unstructured":"Vanover KE et al (2008) A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol Biochem Behav 90:540\u2013544. doi: 10.1016\/j.pbb.2008.04.010","journal-title":"Pharmacol Biochem Behav"},{"key":"4530_CR34","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1002\/mds.21073","volume":"21","author":"NP Visanji","year":"2006","unstructured":"Visanji NP, Gomez-Ramirez J, Johnston TH, Pires D, Voon V, Brotchie JM, Fox SH (2006) Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson\u2019s disease. Mov Disord 21:1879\u20131891. doi: 10.1002\/mds.21073","journal-title":"Mov Disord"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4530-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-017-4530-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4530-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T14:28:29Z","timestamp":1589725709000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-017-4530-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,27]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["4530"],"URL":"https:\/\/doi.org\/10.1007\/s00213-017-4530-z","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,27]]}}}